Patel, R. and Leung, H.Y. (2012) Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Current Pharmaceutical Design, 18(19), pp. 2672-2679.
Full text not currently available from Enlighten.
Abstract
Members of epidermal growth factor receptor (EGFR) or ErbB receptor family play a critical role in a wide range of human cancers. In the past decade, there has been a remarkable progress in the ErbB targeted therapeutics. However, a substantial portion of patients have non-responsive disease or show evidence of tumour relapse following initial success with anti-ErbB agents. Improved insights into the functioning of ErbB receptor family have led to additional second and third generation active anti-ErbB therapies. In this review, we will summary salient features of the ErbB receptor physiology and mechanism involved in abnormal ErbB signalling in tumours. The rationale of anti-ErbB receptor therapies are outlined along with key mechanisms proposed for resistance to treatment. We will also summarise the current model for combined anti-ErbB therapies. In conclusion, increased understanding of the molecular pathways that confer resistance to anti-ErbB therapeutics will be essential in minimising tumour resistance to ErbB targeted treatments.
Item Type: | Articles |
---|---|
Status: | Published |
Refereed: | Yes |
Glasgow Author(s) Enlighten ID: | Leung, Professor Hing and Patel, Dr Rachana |
Authors: | Patel, R., and Leung, H.Y. |
College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences |
Journal Name: | Current Pharmaceutical Design |
ISSN: | 1381-6128 |
ISSN (Online): | 1873-4286 |
Published Online: | 28 February 2012 |
University Staff: Request a correction | Enlighten Editors: Update this record